Widemann honored by Children’s Tumor Foundation
At its Neurofibromatosis Conference in June 2013, the Children’s Tumor Foundation honored NCI’s Brigitte Widemann, M.D., with its von Recklinghausen Award, in recognition of her contributions to neurofibromatosis research and treatment. Widemann, who has been with NCI since 1992, heads the Pharmacology and Experimental Therapeutics Section in the Pediatric Oncology Branch of the Center for Cancer Research. Her contributions include the development of both novel methods of imaging of NF1 tumors and meaningful trial designs and endpoints for NF1 related tumors. In addition, she has built an active clinical trials program of targeted agents for NF1 at the NCI.
The award is named for Friedrich von Recklinghausen, a 19th century German pathologist, who characterized the tumors of NF1, which is still sometimes referred to as “von Recklinghausen syndrome.”
First awarded in 1984, past recipients of the award include NCI Director Francis Collins, M.D., Ph.D., and more recently Nancy Ratner, Ph.D, from Cincinnati Children’s Hospital, and David Gutmann M.D., Ph.D., from the Washington University in St. Louis Alvin J. Siteman Cancer Center.
No hay comentarios:
Publicar un comentario